Schedule 13G ownership disclosure

ArriVent Biopharma Inc

Common Stock, $0.0001 par value · CUSIP: 04272N102

Event date: 2025-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Octagon Capital Advisors LP

    Shares: 1,971,054.00 · Class: 4.9%

  • Octagon Investments Master Fund LP

    Shares: 776,667.00 · Class: 1.9%

  • Octagon Private Opportunities Fund LP

    Shares: 799,911.00 · Class: 2.0%

  • Octagon Special Opportunities Fund LP - Series 4

    Shares: 394,476.00 · Class: 1.0%

  • Ting Jia

    Shares: 1,971,054.00 · Class: 4.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001214659-25-016716
Form type
SCHEDULE 13G/A
Filer
ArriVent BioPharma, Inc.
CIK
CIK 1868279
Filed
Nov 14, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub